HRT warning labels are changing. What should you ask now?

The warning changed, but your questions haven't disappeared

You remember being worried about hormone therapy. Perhaps a warning on the leaflet stayed with you long after the appointment. Now you hear that some of those warnings have been removed, and it feels as though the advice has turned around.

Does that mean the risks have gone away? Was your previous decision wrong? Should you call about a treatment you once ruled out?

Those are reasonable questions. A change in a medicine's label can be important without supplying a complete answer about whether you should take it. The useful place to begin is with the exact change and the exact product.

What the FDA announced

On February 12, 2026, the FDA announced approved labeling changes for six menopause hormone therapy products. These followed an earlier request to manufacturers to revise safety information.

The approved changes removed statements about cardiovascular disease, breast cancer and probable dementia from the products' boxed warnings. A boxed warning is the most prominent warning in a prescription medicine's labeling.

The announcement covered six products. It shouldn't be read as confirmation that every hormone product's leaflet changed at the same time. If you're looking at a particular medicine, its current prescribing information is the relevant document to discuss.

The box is not the whole label

The FDA's consumer explanation makes an important distinction: it did not request removal of cardiovascular disease and breast cancer risks from the Warnings and Precautions section. It also did not request removal of the endometrial cancer boxed warning for systemic estrogen-alone products.

So “removed from the box” doesn't mean “no risk.” The placement and wording of safety information are changing. You still need to understand benefits, possible harms and whether a product fits your history.

A useful question is, “Can you show me what changed and what safety information still applies?” You don't have to interpret a long leaflet on your own.

Which treatment are you actually discussing?

HRT is a broad term. The FDA describes different types, including systemic treatments and local vaginal estrogen products. They aren't all used in the same way or for the same purpose.

Write down the name of the product you're taking or considering. Include the dose and how it's used if you know them. Ask what symptom it is intended to help and why that particular option is being discussed.

If your main concern is vaginal discomfort or painful sex, say that. If it's hot flashes and night sweats, explain their effect on daily life. Our separate article on new treatment guidance for hot flashes addresses treatment recommendations rather than label changes.

You can revisit a decision without judging your past self

Maybe you declined treatment years ago because the risks worried you. Maybe you tried something and stopped because you didn't like how you felt. Neither experience needs to be erased to have another conversation now.

You could say, “I made a decision with the information I had then. Has anything changed that matters for me?” Bring up the reason you declined or stopped, rather than assuming a new label settles it.

Your priorities may have changed too. A symptom that once felt manageable might now affect work or sleep. Or your symptoms may have eased, and you may not want treatment. The point of reviewing a decision is to understand today's options, not to arrive at a predetermined answer.

Ask the pharmacist to make the leaflet useful

If the paperwork feels overwhelming, choose a few questions to bring with it. Which warnings relate to your situation? Which symptoms should prompt medical attention? What should you do if you miss a dose or have a problem using the medicine?

Tell the pharmacist about other medicines and supplements. If you've been considering a product advertised for menopause, our guide to checking product claims explains why the exact ingredients matter.

You can also ask for the explanation in plain language: “Could you tell me the main things I need to remember when I get home?” A written note may be easier to use than trying to remember an entire conversation.

If you're in Canada, remember that an FDA announcement describes US regulation. Ask your pharmacist about the current Canadian information for your specific product. Even within one country, a general news report may not match the leaflet in your hand, so bring the actual package rather than relying on memory.

Leave with a clear next step

Don't start, stop or change a prescribed treatment solely because of a headline. Ask whether the announcement affects your plan and when that plan should be reviewed.

If disrupted sleep is part of what brought you to the appointment, agree on how you'll describe improvement. What would count as useful progress, and when should you report that things aren't improving?

You don't have to choose between dismissing the news and treating it as a guarantee. The label changes offer a reason to ask better questions. The answer still needs to connect the medicine, your health history and what you want help with.

Sources & further reading

• FDA announced approved labeling changes for six menopause hormone therapy products ↗
• FDA's consumer explanation ↗

Read our editorial standards.